The FDA Granted Priority Review to Nivolumab plus Ipilimumab Combined with a Limited Chemotherapy course as First-line Treatment for Patients with Metastatic or Recurrent """" Non-Small Cell Lung Cancer """". La decisión está prevista para el 6 de Agosto .